CervoMed Inc. to Present 32-Week Primary Endpoint Results from RewinD-LB Study at AAIC 2025 Conference Call on July 28

CervoMed to present 32-week results from its Phase 2b RewinD-LB study in dementia with Lewy bodies on July 28, 2025.

Quiver AI Summary

CervoMed Inc. will host a conference call and webcast on July 28, 2025, at 8:00 AM ET to present the primary endpoint results from the 32-week Extension phase of the Phase 2b RewinD-LB study of neflamapimod, a treatment for dementia with Lewy bodies (DLB). The study, which includes 159 patients, is designed to evaluate the effectiveness of neflamapimod while excluding those with Alzheimer's disease co-pathology. The primary outcome measures the change in clinical dementia ratings, alongside various secondary assessments. Funded largely by a $21.3 million grant from the National Institutes of Health, the study spans 43 sites across the U.S., UK, and Netherlands. CervoMed is focused on developing treatments for age-related neurologic disorders and views neflamapimod as a promising candidate for addressing synaptic dysfunction in DLB and similar conditions.

Potential Positives

• Company will present primary endpoint results at 32 weeks from the Phase 2b RewinD-LB study, indicating significant progress in research on dementia with Lewy bodies.
• The conference call and webcast provide an opportunity for investors and stakeholders to engage with the results and learn more about the company's progress and future directions.
• The clinical study is backed by a substantial $21.3 million grant from the National Institutes of Health, underscoring confidence in the research's importance and potential impact.
• CervoMed's investigational treatment, neflamapimod, addresses synaptic dysfunction, positioning the company to target a critical aspect of neurodegenerative diseases.

Potential Negatives

• Company is still in a clinical stage, which may raise concerns about the viability and market potential of its product, neflamapimod.
• The focus on a narrow subgroup (patients with pure DLB) could limit the applicability and market size of their treatment.
• The reliance on a $21.3 million grant from NIH may indicate financial constraints in funding their research independently.

FAQ

What is the primary endpoint of the RewinD-LB study?

The primary endpoint measures the change in the Clinical Dementia Rating – Sum of Boxes over 32 weeks.

When will the new results be shared?

Results will be shared during a conference call on Monday, July 28, 2025, at 8:00 AM ET.

How can I access the conference call and webcast?

You can register for the webcast and access the call using the information provided on CervoMed's website.

What is neflamapimod being evaluated for?

Neflamapimod is being evaluated as a treatment for dementia with Lewy bodies in the ongoing Phase 2b study.

Who is funding the RewinD-LB study?

The study is primarily funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CRVO Insider Trading Activity

$CRVO insiders have traded $CRVO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CRVO stock by insiders over the last 6 months:

• WILLIAM ROBERT ELDER (CFO, GC & Secretary) purchased 4,233 shares for an estimated $35,811

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CRVO Hedge Fund Activity

We have seen 24 institutional investors add shares of $CRVO stock to their portfolio, and 23 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• AWM INVESTMENT COMPANY, INC. added 863,200 shares (+inf%) to their portfolio in Q1 2025, for an estimated $7,898,280
• MORGAN STANLEY added 86,429 shares (+170.7%) to their portfolio in Q1 2025, for an estimated $790,825
• WOODLINE PARTNERS LP removed 74,852 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $684,895
• UBS GROUP AG removed 36,578 shares (-84.3%) from their portfolio in Q1 2025, for an estimated $334,688
• QUBE RESEARCH & TECHNOLOGIES LTD removed 28,021 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $256,392
• CITIZENS FINANCIAL GROUP INC/RI added 26,677 shares (+inf%) to their portfolio in Q1 2025, for an estimated $244,094
• AVANTAX ADVISORY SERVICES, INC. added 25,984 shares (+inf%) to their portfolio in Q1 2025, for an estimated $237,753

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CRVO Analyst Ratings

Wall Street analysts have issued reports on $CRVO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• D. Boral Capital issued a "Buy" rating on 06/11/2025
• Chardan Capital issued a "Buy" rating on 05/12/2025
• Canaccord Genuity issued a "Buy" rating on 03/18/2025
• Roth MKM issued a "Buy" rating on 03/18/2025
• Jones Trading issued a "Buy" rating on 03/13/2025

To track analyst ratings and price targets for $CRVO, check out Quiver Quantitative's $CRVO forecast page.

$CRVO Price Targets

Multiple analysts have issued price targets for $CRVO recently. We have seen 5 analysts offer price targets for $CRVO in the last 6 months, with a median target of $15.0.

Here are some recent targets:

• Jason Kolbert from D. Boral Capital set a target price of $10.0 on 06/11/2025
• Daniil Gataulin from Chardan Capital set a target price of $15.0 on 05/12/2025
• Boobalan Pachaiyappan from Roth MKM set a target price of $20.0 on 03/18/2025
• Sumant Kulkarni from Canaccord Genuity set a target price of $21.0 on 03/18/2025
• Soumit Roy from Jones Trading set a target price of $15.0 on 03/13/2025

Full Release

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference

^®

(AAIC) 2025

Conference call and webcast to be held Monday, July 28 at 8:00 AM ET

BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8:00 AM ET to share new results, including the primary endpoint results at 32-weeks of the Extension phase, from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies (DLB). The details of the upcoming late-breaking presentations at AAIC 2025 can be found

here

.

Conference Call / Webcast Details



The company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Monday, July 28, 2025.

To register for the webcast, please click



here



.

Participants should dial 1-877-425-9470 (domestic) or 1-201-389-0878 (international) with the code 13755139.

To access the Call me™ feature, which avoids having to wait for an operator, click

here

.

The live webcast and replay will be available under “Events & Presentations” in the Investor Relations section of the Company’s website,

https://www.cervomed.com

.

About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies and Next Steps



The RewinD-LB clinical study is a randomized, 16-week, double-blind, placebo-controlled clinical study evaluating oral neflamapimod (40mg TID), with a 32-week neflamapimod only treatment Extension phase, in 159 patients with DLB. Patients with Alzheimer’s disease co-pathology, as assessed by plasma ptau181 levels, were excluded from the study. Compared to patients with “pure” DLB – who may comprise up to 50% of the total diagnosed DLB patient population at any given time – DLB patients with AD co-pathology have significant, irreversible neuronal loss in the hippocampus that limits response to treatment. The primary outcome measure in the study is change in the Clinical Dementia Rating – Sum of Boxes, and secondary endpoints include Alzheimer's Disease Cooperative Study - CGIC, the Timed Up and Go test, and a cognitive test battery. The RewinD-LB study is funded primarily by a $21.3 million grant from the National Institutes of Health’s National Institute on Aging, which is expected to be disbursed over the course of the study as costs are incurred. The study includes 43 sites across in the United States, the United Kingdom, and the Netherlands. Participants completing the 16-week Initial phase of the study were able to continue in the study while receiving neflamapimod treatment for an additional 32-week Extension phase, within which the same efficacy assessments were conducted during the first 16 weeks as were obtained during the Initial phase.

About CervoMed



CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:



PJ Kelleher


LifeSci Advisors



Investors@cervomed.com



617-430-7579

Media



Argot Partners



cervomed@argotpartners.com



212-600-1902

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.